Table 1.
Baseline characteristics of patients ≥60, ≥65, and ≥70 years with squamous NSCLC
| Characteristic | ≥60 years
|
≥65 years
|
≥70 years
|
|||
|---|---|---|---|---|---|---|
| nab-P/C (n=106) |
P/C (n=110)a |
nab-P/C (n=67) |
P/C (n=70)b |
nab-P/C (n=35) |
P/C (n=30)c |
|
| Age, median (range), years | 67 (60–81) | 67 (60–84) | 70 (65–81) | 69 (65–84) | 72 (70–81) | 72 (70–84) |
| Sex, n (%) | ||||||
| Male | 91 (86) | 94 (85) | 59 (88) | 60 (86) | 30 (86) | 26 (87) |
| Female | 15 (14) | 16 (15) | 8 (12) | 10 (14) | 5 (14) | 4 (13) |
| Race, n (%) | ||||||
| White | 89 (84) | 103 (94) | 53 (79) | 66 (94) | 26 (74) | 28 (93) |
| Black or African American | 5 (5) | 2 (2) | 5 (7) | 1 (1) | 3 (9) | 0 |
| Other | 12 (11) | 5 (5) | 9 (13) | 3 (4) | 6 (17) | 2 (7) |
| ECOG PS, n (%) | ||||||
| 0 | 24 (23) | 19 (17) | 16 (24) | 12 (17) | 7 (20) | 8 (27) |
| 1 | 82 (77) | 91 (83) | 51 (76) | 58 (83) | 28 (80) | 22 (73) |
| Region, n (%) | ||||||
| Eastern Europe | 74 (70) | 83 (75) | 41 (61) | 48 (69) | 17 (49) | 17 (57) |
| North America | 23 (22) | 22 (20) | 19 (28) | 19 (27) | 13 (37) | 11 (37) |
| Asia/Pacific | 9 (8) | 5 (5) | 7 (10) | 3 (4) | 5 (14) | 2 (7) |
| Australia/New Zealand | 0 | 0 | 0 | 0 | 0 | 0 |
| Smoking status, n (%) | ||||||
| Never smoked | 16 (15) | 16 (15) | 11 (16) | 9 (13) | 7 (20) | 3 (10) |
| Smoked and quit smoking | 35 (33) | 38 (35) | 26 (39) | 27 (39) | 14 (40) | 11 (38) |
| Smoked and currently smokes | 55 (52) | 54 (50) | 30 (45) | 33 (48) | 14 (40) | 15 (52) |
Notes:
a
n=108 for smoking status;
b
n=69 for smoking status;
c
n=29 for smoking status.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; nab-P/C, nab-paclitaxel/carboplatin; NSCLC, non-small cell lung cancer; P/C, paclitaxel/carboplatin.